Inhibrx Current Ratio 2020-2022 | INBX
Inhibrx current ratio from 2020 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Inhibrx Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-03-31 |
$0.15B |
$0.02B |
7.48 |
| 2021-12-31 |
$0.14B |
$0.02B |
6.20 |
| 2021-09-30 |
$0.12B |
$0.03B |
4.73 |
| 2021-06-30 |
$0.13B |
$0.02B |
6.06 |
| 2021-03-31 |
$0.11B |
$0.03B |
4.07 |
| 2020-12-31 |
$0.13B |
$0.03B |
4.21 |
| 2020-09-30 |
$0.13B |
$0.04B |
3.80 |
| 2020-06-30 |
$0.00B |
|
0.00 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.533B |
$0.007B |
|
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
|
